MoonLake Immunotherapeutics (MLTX)
39.74
-1.12
(-2.74%)
USD |
NASDAQ |
May 17, 16:00
39.74
0.00 (0.00%)
Pre-Market: 20:00
MoonLake Immunotherapeutics Cash from Investing (Quarterly): -28.80M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -28.80M |
| December 31, 2023 | 116.87M |
| September 30, 2023 | -174.38M |
| June 30, 2023 | 12.68M |
| March 31, 2023 | 19.65M |
| Date | Value |
|---|---|
| December 31, 2022 | 9.901M |
| September 30, 2022 | -42.23M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -0.016M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-174.38M
Minimum
Sep 2023
116.87M
Maximum
Dec 2023
-9.592M
Average
--
Median
Jun 2022
Cash from Investing (Quarterly) Benchmarks
| Qiagen NV | 6.431M |
| LENZ Therapeutics Inc | 18.00M |
| AC Immune SA | -26.96M |
| CRISPR Therapeutics AG | -97.80M |
| Addex Therapeutics Ltd | -0.0012M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.95M |
| Cash from Financing (Quarterly) | 50.98M |
| Free Cash Flow | -48.91M |
| Free Cash Flow Per Share (Quarterly) | -0.242 |
| Free Cash Flow Yield | -2.24% |